Literature DB >> 15148009

Potent analgesics are more expensive for patients in developing countries: a comparative study.

Liliana De Lima1, Catherine Sweeney, J Lynn Palmer, Eduardo Bruera.   

Abstract

Opioids are some of the most important analgesic medications for the management of both moderate to severe pain and several are included on the World Health organization (WHO) list of essential drugs. Opioid costs in developing countries have been reported to be higher than those in developed nations. This study documents retail prices and availability of several potent opioids in a number of developing and developed countries. Pain and Palliative Care specialists currently working in their countries were asked to collect data on the retail cost of a 30 day supply of 15 different opioid preparations in 5 developing and 7 developed countries. Data were analyzed to compare costs and costs as a percentage of gross national product (GNP) per capita per month. Opioid costs and availability varied widely in both developing and developed countries. Forty five of 75 opioid preparations were available in developing countries (40% of medications studied were not available) and 76 of 105 preparations were available in the developed countries (28% not available). In US dollars, the median cost of opioids differed between developed and developing countries ($53 and $112 respectively) The median costs of all opioid preparations as a percentage of GNP per capita per month were 36% for developing and 3% for developed nations; the difference was statistically significant (p < 0.001). In developing countries 23 of 45 (51%) of opioid dosage forms cost more than 30% of the monthly GNP per capita, versus only three of 76 (4%) in developed countries. The relative cost of opioids to income is higher in developing countries. Our data suggest that in developing countries opioid access for the majority of patients is likely to be limited by cost, and development of palliative care programs will require heavy or total subsidization of opioid costs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15148009

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  18 in total

Review 1.  Improving the availability and accessibility of opioids for the treatment of pain: the International Pain Policy Fellowship.

Authors:  Snezana Bosnjak; Martha A Maurer; Karen M Ryan; Marta X Leon; Gabriel Madiye
Journal:  Support Care Cancer       Date:  2011-06-03       Impact factor: 3.603

2.  Promoting science in a pragmatic world: not (yet) time for partial opioid rotation.

Authors:  Florian Strasser
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

3.  Intermittent subcutaneous opioids for the management of cancer pain.

Authors:  Henrique A Parsons; Abdul Shukkoor; Hue Quan; Marvin O Delgado-Guay; J Lynn Palmer; Robin Fainsinger; Eduardo Bruera
Journal:  J Palliat Med       Date:  2008-12       Impact factor: 2.947

4.  Cancer pain--progress and ongoing issues in Africa.

Authors:  Olaitan Soyannwo
Journal:  Pain Res Manag       Date:  2009 Sep-Oct       Impact factor: 3.037

Review 5.  Pain management in low- and middle-income countries.

Authors:  W W Morriss; C J Roques
Journal:  BJA Educ       Date:  2018-07-14

Review 6.  Access to opioid analgesics and pain relief for patients with cancer.

Authors:  Shalini Dalal; Eduardo Bruera
Journal:  Nat Rev Clin Oncol       Date:  2013-01-15       Impact factor: 66.675

7.  Using a morphine equivalence metric to quantify opioid consumption: examining the capacity to provide effective treatment of debilitating pain at the global, regional, and country levels.

Authors:  Aaron M Gilson; Martha A Maurer; Karen M Ryan; Paul J Rathouz; James F Cleary
Journal:  J Pain Symptom Manage       Date:  2012-09-24       Impact factor: 3.612

8.  The other opioid crisis: the situation in low-resource countries.

Authors:  Clare Roques; Wayne Morriss; Carolina Haylock-Loor
Journal:  Can J Anaesth       Date:  2022-07-18       Impact factor: 6.713

9.  Access to pain treatment as a human right.

Authors:  Diederik Lohman; Rebecca Schleifer; Joseph J Amon
Journal:  BMC Med       Date:  2010-01-20       Impact factor: 8.775

Review 10.  New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

Authors:  Emma Beard; Lion Shahab; Damian M Cummings; Susan Michie; Robert West
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.